Susceptibility-weighted MRI of extrapyramidal brain structures in Parkinsonian disorders. Issue 26 (June 2016)

• Record Type: Journal Article
• Authors: Schneider, Eva; Ng, Kia-Min; Yeoh, Chooi-Sum; Rumpel, Helmut; Fook-Chong, Stephanie; Li, Hui-Hua; Tan, Eng-King; Chan, Ling-Ling
• Other Names: Rosales. Raymond section editor.
• Is Part Of: Medicine. Volume 95:Issue 26(2016)
• Publication Date: 2016-06
• Subjects: imaging -- Parkinsonian disorders -- susceptibility-weighted MRI; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000003730
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Susceptibility-weighted MRI (SWI) is sensitive to T2 * effects and mineralization. We investigated differences in the extrapyramidal brain structures on SWI between Parkinson disease (PD) and postural instability gait disorder (PIGD) patients and correlated the SWI values with the degree of gait dysfunction. Forty patients diagnosed with PD and PIGD underwent 3 Tesla magnetic resonance imaging (MRI) brain study. An SWI sequence (TE/TR/FA 20/33/15) was used. Ten regions of interest were placed in the midbrain and basal ganglia by 2 independent raters blinded to subject data and quantitatively evaluated. The inter-rater reliability between the raters was excellent (interclass correlation coefficient >0.8). The SWI intensity values in all regions were on average lower in PIGD than in PD patients, with the lowest results found in globus pallidus. Multivariate analysis showed a lower SWI hypointensity in the putamen and globus pallidus in PIGD compared with PD patients, with a similar trend for the other basal ganglia nuclei. Pearson correlation analysis showed a statistically significant positive correlation between SWI putaminal hypointensity and the Tinetti total score (r = 0.39, P = 0.01) in both PD and PIGD. SWI putaminal hypointensity may be a useful imaging marker in prospective evaluation for clinical progression for Parkinsonian disorders.